BioPharma Credit PLC USDLSE: BPCP

BioPharma Credit PLC USD: Director/PDMR Shareholding

· Issued by BioPharma Credit PLC USD via RNS

Summary by 6ix AI

Nigel Reynolds, a director of BioPharma Credit PLC, bought 476.78 ordinary shares at $0.988 each on November 6, 2026, as part of a dividend reinvestment plan, in which dividends are used to buy more shares.

Key details

  • The shares are ordinary shares of $0.01 each, and the purchase took place on the London Stock Exchange.
  • This is an initial notification of a share dealing by a person discharging managerial responsibilities, meaning a director or senior manager of the company.

6ix AI wrote this summary from the release below and checked it against the release.

BioPharma Credit PLC
10 November 2026

BIOPHARMA CREDIT PLC

Notification of Transactions by

Persons Discharging Managerial Responsibilities and

Persons Closely Associated with them

1.

Details of person discharging managerial responsibilities/person closely associated with them

a)

Name

Nigel Reynolds

2.

Reason for the notification

a)

Position / status

Director of BioPharma Credit PLC

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BioPharma Credit PLC

b)

LEI

213800AV55PYXAS7SY24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares of $0.01 each

GB00BDGKMY29

b)

Nature of the transaction

Purchase of Shares (acquired as part of dividend reinvestment plan)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.988

476.78

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

06.11.2026

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BioPharma Credit PLC USD on 6ix

Earlier from BioPharma Credit PLC USD

Later from BioPharma Credit PLC USD

All BioPharma Credit PLC USD news releases